Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Ertapenem

Ertapenem

Carbapenem (IV/IM) β€” once-daily

ESBLCAPq24hΞ²-lactam

Indication

Complicated intra-abd β€’ complicated UTI β€’ CAP (IV) β€’ diabetic foot (combo) β€’ ESBL (selected)

At a glance

INDICATIONS (CORE USE)

Convenient q24h carbapenem for many community-onset serious infections β€” **NO reliable Pseudomonas or Acinetobacter**.

ADULT DOSE (STANDARD)

1 g IV/IM q24h

MAX DOSE

1 g/day adult standard

Route

IV, IM

PEDIATRIC DOSE

15 mg/kg q12h (max 1 g) in peds β€” verify monograph (not always q24h in children)

Do not miss

Must-not-miss safety points

Major warning

- Ξ²-lactam anaphylaxis - **No Pseudomonas / Acinetobacter** β€” wrong empiric choice in HAP/VAP with those risks - Seizure risk class effect β€” renal/hepatic combined adjustment per label - Valproate interaction (carbapenem class)

Indications

USE IF: Community-onset complicated infections where once-daily IV helps transitions; ESBL UTI/pyelo when susceptible. AVOID IF: Pseudomonas/Acinetobacter risk; meningitis (inadequate CSF penetration); valproate without plan.

Primary

  • Complicated intra-abdominal infection (with source control)
  • Complicated UTI including pyelonephritis (susceptible organisms)
  • Community-acquired pneumonia requiring IV therapy when pathogen coverage appropriate

Secondary

  • Acute pelvic infection combinations
  • Diabetic foot infection regimens when pseudomonas risk low and guideline supports

Other

  • Outpatient OPAT selection when logistics favor q24h

Dosing

STANDARD (ADULT PO)

1 g IV/IM q24h

ADULT DOSE

1 g IV/IM q24h; infusion ~30 min

PEDIATRIC DOSE

Pediatric schedule often **BID** β€” do not assume adult q24h in children.

MAX DOSE

1 g per dose standard adult

Practical Note

IM for OPAT only when appropriate volume tolerated.

Warnings

Clinical warnings

  • **Ξ²-lactam allergy β€” immediate** (anaphylaxis, angioedema, bronchospasm, hypotension) β†’ **avoid** this agent; use non–β-lactam alternative
  • **Ξ²-lactam allergy β€” non-severe** (maculopapular rash without systemic anaphylaxis features) β†’ **caution**; risk/benefit + allergy/ID pathway; graded challenge or test dose **only** per protocol β€” do not dismiss automatically
  • **Neurotoxicity:** encephalopathy, confusion, myoclonus, seizures β€” **higher risk with CKD, elderly, dose accumulation** (notably cefepime, carbapenems, high-dose penicillins)
  • New CNS symptoms + renal impairment on IV Ξ²-lactam β†’ **hold dose**, check levels/exposure, rule out other causes
  • C. diff
  • Drug reaction with eosinophilia systemic symptoms (DRESS) rare

Adverse effects

  • diarrhea
  • infusion site issues
  • headache

Contraindications

  • Hypersensitivity to ertapenem

Drug interactions

  • Valproate
  • Warfarin monitoring

Special populations

Pediatrics

15 mg/kg q12h (max 1 g) in peds β€” verify monograph (not always q24h in children)

Pregnancy

Animal data limited β€” use if benefit clear

Lactation

caution limited data.

Renal impairment

CrCl <30 β†’ 500 mg q24h per label; dialysis supplemental doses. **CrCl scaffold (FMBM β€” titrate to FDA/SFDA label + institutional pharmacy nomogram):** - **CrCl β‰₯50** β†’ standard interval (per Adult dosing card) - **CrCl 10–50** β†’ extend interval and/or reduce dose (often q12–24h or ↓ dose β€” **product-specific**) - **CrCl <10** β†’ maximal interval extension / dose reduction; **HD: redose post-dialysis** per protocol; AKI β†’ re-estimate CrCl; **neuro signs** β†’ hold/adjust

Hepatic impairment

Mild–moderate hepatic + severe renal β†’ per label combined adjustment.

Elderly

Renal dosing.

Administration

Reconstitute with compatible diluent; IV or deep IM.

Monitoring

  • Monitor: - ICU or CKD β†’ **creatinine daily** β†’ mandatory dose reduction; maladjustment β†’ **neurotoxicity** - **Valproate co-therapy** β†’ avoid overlap; if unavoidable β†’ VPA level + neurology (seizure breakthrough) - CRE / MDR context β†’ infection control + stewardship documentation - Intra-abd: re-image or re-operate if not improving despite appropriate therapy
  • Recheck: - No clinical improvement at 48–72h β†’ reassess diagnosis, resistance, source control, and drug interactions - If targets not met after reassessment of dose, organ function, and interactions β†’ escalate per protocol (DO NOT continue blindly)

Overdose / toxicity

Clinical Picture

**Life-threatening (first):** **CNS toxicity** β€” seizures, encephalopathy, agitation, myoclonus, coma (**↑ CKD, elderly, accumulation**; cefepime, carbapenems, high-dose penicillins). **Allergic:** anaphylaxis / angioedema (separate pathway). **Secondary:** nausea/vomiting/diarrhea mainly with acute massive **oral** co-ingestion or local infusion reaction.

Immediate Actions

Stop Ξ²-lactam β†’ ABCs β†’ **seizure precautions**; benzos if seizures; check renal function / dose vs CrCl; anaphylaxis β†’ epinephrine + ACLS

Antidote

No specific antidote; treat complications (e.g. anaphylaxis β†’ epinephrine per ACLS)

Decontamination

Stop infusion; recent large PO load β†’ charcoal if protected airway + early presentation

Escalation

Status epilepticus, coma, refractory seizures β†’ **ICU**; **severe CNS toxicity or AKI with accumulation β†’ consider hemodialysis** for dialyzable agents β€” nephrology + pharmacy; persistent anaphylaxis β†’ ICU

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield Summary

**q24h** carbapenem β€” logistics win. **Coverage hole: Pseudomonas / Acinetobacter.** Valproate.

Clinical pearls

OPAT pathway drug when spectrum fits. Pediatric dosing β‰  adult schedule. Stewardship: step down oral when stable. *Stewardship (all antimicrobials):* Empiric choice β†’ syndrome severity + **local antibiogram**; shortest effective course.

Stewardship & safety

  • No Pseudomonas
  • Valproate
  • Renal 500 mg rule

Pharmacokinetics

Long half-life allows q24h adults; highly protein bound; hepatic glucuronidation + renal.

Mechanism of action

Carbapenem β€” broad except Pseudomonas/Acinetobacter.

Common brand names

Saudi Arabia

Invanz, Ertapenem

Global

(placeholder β€” verify local formulary)

Common trade names are curated examples only β€” formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

  • Empiric choice β†’ tie to syndrome, severity, and local antibiogram β€” not habit.
  • IV β†’ PO step-down when oral bioavailability and susceptibility allow.
  • Do not use antibiotics for uncomplicated viral illness β€” stewardship.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • Sanford Guide
  • IDSA / ESCMID (indication-specific)
  • Local antimicrobial stewardship / hospital formulary
  • FDA / SFDA / regional product labeling
  • Sanford Guide
  • IDSA / ESCMID (indication-specific)
  • Local antimicrobial stewardship / hospital formulary
  • FDA / SFDA / regional product labeling

Do not miss

  • Uncomplicated viral URI/bronchitis β†’ antibiotics rarely indicated
  • Narrow or stop when susceptibilities + clinical stability allow
  • Using ertapenem for nosocomial pseudomonal pneumonia β†’ predictable failure.
  • No Pseudomonas
  • Valproate
  • Renal 500 mg rule